Citigroup
CRBP icon

Citigroup’s Corbus Pharmaceuticals CRBP Stock Holding History

Citigroup’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-33
Closed -$5K – 7554
2020
Q1 		$5K Sell
33
-1,464
-98% -$248K ﹤0.01% 7260
2019
Q4 		$245K Sell
1,497
-13
-0.9% -$1.92K ﹤0.01% 5014
2019
Q3 		$221K Sell
1,510
-210
-12% -$36.6K ﹤0.01% 5066
2019
Q2 		$358K Buy
1,720
+77
+5% +$16.5K ﹤0.01% 4757
2019
Q1 		$343K Buy
1,643
+693
+73% +$153K ﹤0.01% 4569
2018
Q4 		$166K Buy
950
+757
+392% +$151K ﹤0.01% 5206
2018
Q3 		$44K Sell
193
-344
-64% -$55.6K ﹤0.01% 6626
2018
Q2 		$81K Sell
537
-700
-57% -$127K ﹤0.01% 5897
2018
Q1 		$226K Buy
1,237
+464
+60% +$104K ﹤0.01% 4842
2017
Q4 		$165K Sell
773
-34
-4% -$7.28K ﹤0.01% 5214
2017
Q3 		$173K Buy
807
+667
+476% +$130K ﹤0.01% 5104
2017
Q2 		$26K Sell
140
-280
-67% -$54.9K ﹤0.01% 6151
2017
Q1 		$104K Buy
+420
New +$103K ﹤0.01% 5180

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Citigroup's CRBP Position: Q2 2026 in Review

Citigroup reduced its Corbus Pharmaceuticals (CRBP) stake by 32% in Q2 2026, selling an estimated $51K and leaving 11,319 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #4653.

Citigroup first reported a position in CRBP in Q1 2017 and has held it in 29 quarters since. The position peaked at $685K in Q2 2020. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Citigroup held 11,319 shares of Corbus Pharmaceuticals worth $106K as of Q2 2026.
  • Citigroup sold 5,389 Corbus Pharmaceuticals shares in Q2 2026, an estimated $51K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4653 holding.
  • Citigroup first reported a position in Corbus Pharmaceuticals in Q1 2017 and has held it in 29 quarters since.
  • Citigroup's Corbus Pharmaceuticals position peaked at $685K in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.